| NCT ID | NCT07362303 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Neuralert Technologies LLC |
| Condition | Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,200 participants |
| Start Date | 2026-03-26 |
| Primary Completion | 2028-01-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,200 participants in total. It began in 2026-03-26 with a primary completion date of 2028-01-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The Neuralert monitoring system, a non-invasive device worn on each wrist, is designed to provide continuous monitoring and expedited recognition of stroke by identifying asymmetry in the extremities, facilitating patient treatment and improving outcomes. This study is designed to evaluate the safety and effectiveness of the Neuralert Monitor. This study aims to show that the device produces fewer than 2 false alarms per patient per day on average, and that the device detects stroke with a sensitivity significantly greater than a device producing 2 random alerts per day.
Eligibility Criteria
Inclusion Criteria: (all must be yes) 1. Male or female age ≥ 22 years 2. Admitted or planned admission to one of the participating hospitals and followed by the Cardiothoracic (CT) Surgery or Vascular Surgery services 3. Considered at high risk for stroke while in the hospital based on: * Interventions or procedures that are high-risk for stroke performed during the hospitalization, which may include: * Intracardiac surgical or endovascular procedures, including valve replacement * Ascending aorta or aortic arch surgical or endovascular repair * Open surgical or endovascular carotid revascularization * Other cardiac procedures along with a high-risk medical history: * Age ≥ 80 years * Prior stroke/ transient ischemic attack (TIA) * Hypercoagulable state (i.e., prior clotting events attributed to active malignancy or a diagnosed thrombophilia) requiring lifelong anticoagulation * Severely reduced left ventricular cardiac ejection fraction (i.e., \<30%) or anterior left ventricular wall akinesis * Atrial fibrillation Exclusion Criteria: (all must be no) 1. Any medical or psychological conditions that, in the opinion of the investigator, would compromise the subject's safety or successful participation in the study 2. Baseline preoperative asymmetric upper extremity weakness as assessed by the Investigator, defined as a differential in the NIHSS upper extremity motor score between the two arms of \>0 3. Above the wrist amputation 4. Unwilling to provide informed consent or no legally authorized representative willing to provide consent if the patient is unable 5. Currently imprisoned
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07362303 clinical trial?
This trial is open to participants of all sexes, aged 22 Years or older, studying Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07362303 currently recruiting?
Yes, NCT07362303 is actively recruiting participants. Contact the research team at cucchiar@pennmedicine.upenn.edu for enrollment information.
Where is the NCT07362303 trial being conducted?
This trial is being conducted at Philadelphia, United States.
Who is sponsoring the NCT07362303 clinical trial?
NCT07362303 is sponsored by Neuralert Technologies LLC. The trial plans to enroll 1,200 participants.